Amylyx is an IND-stage therapeutics company developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease that targets the neuroinflammation and nerve cell death that characterize these disorders. The company’s therapeutic, AMX0035, is a proprietary, synergistic combination of existing compounds that blocks nerve cell death and neurotoxic inflammation. The approach has exhibited strong efficacy across nonspecific models of neurodegenerative disease as well as in transgenic models of ALS and Alzheimer’s. AMX0035 is expected to enter a pivotal, proof-of-concept clinical trial in ALS in 2016. Following a successful initial clinical trial, AMX0035 will be tested in a proof of concept trial of Alzheimer’s disease.